ClinicalTrials.gg
WithdrawnNCT03338751DECIPHERUpdated Nov 9, 2017

Determine the Effect on Cognitive Impairment Measures by Providing Hearing-Assistance to Skilled Nursing Facility Residents

An interventional study of cognitive testing with HAD (PockeTalker) First and Cognitive testing without HAD First in Hearing Impairment, sponsored by NYU Langone Health. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-09.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Health services research

Why this study was withdrawn
Unfunded Pilot Study
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to see if a commercially available hearing assistance device called the PockeTalker has an effect on performance on cognitive (memory and thinking) tests among skilled nursing facility residents.

Investigators are asking residents to perform cognitive tests with and without hearing assistance equipment known as PockeTalkers. This study will be conducted at one urban Skilled Nursing Facility (SNF) with the goal of understanding the extent to which hearing impairment impacts commonly used cognitive impairment measures for clinical assessment. Cognitive performance will be measured, cerumen occlusion, and perceived hearing.

02

Conditions studied

  • Hearing Impairment

Browse trials for

03

In context

Hearing Loss

1,109 studies on the registry are indexed under Hearing Loss; 233 are open to participants now.

Browse Hearing Loss studies →

Lead sponsor

NYU Langone Health is the lead sponsor of 1,421 studies on the registry; 254 are open to participants now.

Of its 231 completed or terminated interventional studies of FDA-regulated products, 195 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • admitted to unit of intervention
  • ability to communicate and follow simple commands
  • capacity to consent assessed with standard questions used to assess capacity or having a surrogate who can provide consent.

Exclusion criteria

Exclusion Criteria:

  • not on the unit of intervention
  • obtunded or comatose state
  • inability to communicate verbally
  • inability to consent and without surrogate
  • non-English speaking
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Hearing Assistance Device (HAD) First

    Tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second. Participants randomized to HAD first will use a Hearing Aid Device.

    Diagnostic Test: cognitive testing with HAD (PockeTalker) First · Diagnostic Test: Cognitive testing without HAD First

  • Active comparator
    No Hearing Assistance Device (HAD) First

    Sham hearing aid device

    Diagnostic Test: cognitive testing with HAD (PockeTalker) First · Diagnostic Test: Cognitive testing without HAD First

Interventions

  • Diagnostic testcognitive testing with HAD (PockeTalker) First

    tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second.

    Also known as: PockeTalker Hearing Aid Device

  • Diagnostic testCognitive testing without HAD First

    tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second.

06

What researchers measure

Primary outcomes

  1. Measure of Cognitive function using Mini-Cog

    three-item recall and a clock draw test. 24 Medical assistants have been trained and have employed this test successfully in primary care practices. The Mini-Cog has test characteristics that are comparable to any other brief instrument and exceeds most in accuracy or predictive quality.

    Time frame: 20 Minutes

  2. Perceived Hearing measured by Hearing Handicap Inventory for the Elderly-Screening Version (HHIE)

    HHIE-S is a valid, robust test for identifying hearing-impaired elderly, irrespective of the audiometric definition used to finally diagnose hearing difficulties.

    Time frame: 20 Minutes

07

Study locations

1 site
  • New York University School of Medicine
    New York, New York 10016, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2018; primary completion for Jan 2019, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2017
First posted
Nov 9, 2017
StartEst.
Jan 2018
Primary completionEst.
Jan 2019
CompletionEst.
Jan 2019
Last update
Nov 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03338751
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Nov 9, 2017
Start date
Jan 2018 (estimated)
Primary completion
Jan 2019 (estimated)
Completion
Jan 2019 (estimated)
Last update
Nov 9, 2017

Study contacts

Joshua Chodosh, MD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion